Mantle Cell Lymphoma clinical trials

Explore recruiting mantle cell lymphoma clinical trials.

Recruiting mantle cell lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Mantle Cell Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Bcl 2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Germany, Poland, France, Spain, Belgium, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Glofitamab Combined With Pirtobrutinib in Relapsed/Refractory Patients with Mantle Cell Lymphoma Followed by an Extension in Treatment Naïve Patients (PLATO)

Denmark, Sweden, Norway, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA)

Finland, Norway, Denmark, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase II, multicenter study of GlOfitamab in patients with mantle cell Lymphoma and inaDequate response or relapse following CAR T-cell therapy (GOLD)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma

Poland

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Mantle Cell Lymphoma trials by city

Mantle Cell Lymphoma in Toronto Mantle Cell Lymphoma in Vancouver Mantle Cell Lymphoma in Montreal Mantle Cell Lymphoma in Calgary Mantle Cell Lymphoma in Edmonton Mantle Cell Lymphoma in Ottawa Mantle Cell Lymphoma in Winnipeg Mantle Cell Lymphoma in Quebec City Mantle Cell Lymphoma in Hamilton Mantle Cell Lymphoma in Kitchener Mantle Cell Lymphoma in London Mantle Cell Lymphoma in Halifax Mantle Cell Lymphoma in New York Mantle Cell Lymphoma in Los Angeles Mantle Cell Lymphoma in Chicago Mantle Cell Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease